Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Beth Eaby-Sandy"'
Autor:
Christine M. Lovly, Siraj M. Ali, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Deborah Morosini, Jens Meiler, Jonathan H. Sheehan, Yingjun Yan, Heidi Chen, Andrew Whiteley, Tiziana Vavalà, Beth Eaby-Sandy, Satyanarayan K. Reddy, Suresh S. Ramalingam, Vijay Peddareddigari, Taofeek K. Owonikoko, Eiki Ichihara, Kyle Gowen, Barbara J. Gitlitz, Francis J. Giles, Young Kwang Chae, Jean-Nicolas Gallant, Kartik Konduri
Supplementary Methods, Supplementary References, Supplementary Table Legends, and Supplementary Figure Legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5ff55dd2169cc77c991bc6bb6e3dc5
https://doi.org/10.1158/2159-8290.22531335
https://doi.org/10.1158/2159-8290.22531335
Autor:
Christine M. Lovly, Siraj M. Ali, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Deborah Morosini, Jens Meiler, Jonathan H. Sheehan, Yingjun Yan, Heidi Chen, Andrew Whiteley, Tiziana Vavalà, Beth Eaby-Sandy, Satyanarayan K. Reddy, Suresh S. Ramalingam, Vijay Peddareddigari, Taofeek K. Owonikoko, Eiki Ichihara, Kyle Gowen, Barbara J. Gitlitz, Francis J. Giles, Young Kwang Chae, Jean-Nicolas Gallant, Kartik Konduri
Supplementary Tables S1 - S3. Supplementary Table S1. Summary of EGFR alterations in NSCLC identified by FoundationOne. Supplementary Table S2. Summary of genomic coordinates for the kinase fusions identified in this study. Supplementary Table S3. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db98bc3806deffc1adf56b29743aafdf
https://doi.org/10.1158/2159-8290.22531332
https://doi.org/10.1158/2159-8290.22531332
Autor:
Christine M. Lovly, Siraj M. Ali, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Deborah Morosini, Jens Meiler, Jonathan H. Sheehan, Yingjun Yan, Heidi Chen, Andrew Whiteley, Tiziana Vavalà, Beth Eaby-Sandy, Satyanarayan K. Reddy, Suresh S. Ramalingam, Vijay Peddareddigari, Taofeek K. Owonikoko, Eiki Ichihara, Kyle Gowen, Barbara J. Gitlitz, Francis J. Giles, Young Kwang Chae, Jean-Nicolas Gallant, Kartik Konduri
Supplementary Figures S1 - S10. Supplementary Figure S1. Additional information for Patient 1. Supplementary Figure S2. Additional information for Patient 2. Supplementary Figure S3. Additional information for Patient 3. Supplementary Figure S4. Addi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48e88c6e94da7f5cc24a334b865d42c6
https://doi.org/10.1158/2159-8290.22531338.v1
https://doi.org/10.1158/2159-8290.22531338.v1
Autor:
Elizabeth Gilbert, Anil Vachani, Jeffrey C. Thompson, Christine Ciunci, Shawn Kothari, Roger B. Cohen, Faith Mutale, Stephen J Bagley, Charu Aggarwal, Peter Gabriel, Gloria Dilullo, Corey J. Langer, Joshua Bauml, John A. Kosteva, Susan Stonehouse-Lee, Victoria Sherry, Beth Eaby-Sandy, Evan W. Alley, Tracey L. Evans
Publikováno v:
Lung Cancer. 106:1-7
Efficient use of nivolumab in non-small-cell lung cancer (NSCLC) has been limited by the lack of a definitive predictive biomarker. In patients with metastatic melanoma treated with ipilimumab, a pretreatment neutrophil-to-lymphocyte ratio (NLR)5 has
Autor:
Tzewah V, Leung, Mitchell E, Hughes, Christine G, Cambareri, Daniel J, Rubin, Beth, Eaby-Sandy
Publikováno v:
Journal of the Advanced Practitioner in Oncology
Chemotherapy, and now targeted therapies and immunotherapies, are widely used for the management of patients with all stages of lung cancer. Some challenges present when patients are receiving concomitant hemodialysis for various comorbid conditions.
Autor:
Beth Eaby-Sandy
Publikováno v:
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners ISBN: 9783030165499
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfca87e96943bf727dbee9391f35e16d
https://doi.org/10.1007/978-3-030-16550-5_1
https://doi.org/10.1007/978-3-030-16550-5_1
Autor:
Beth Eaby-Sandy, Michelle Turner
Publikováno v:
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners ISBN: 9783030165499
While there has been significant progress in the treatments for lung cancer over the past decade, it remains the leading cause of cancer death as of 2019. The discovery of the epidermal growth factor receptor (EGFR) mutation in lung cancer cells has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2965dbf1964e40faa8d01d55847e36a0
https://doi.org/10.1007/978-3-030-16550-5_3
https://doi.org/10.1007/978-3-030-16550-5_3
Autor:
Beth Eaby-Sandy
Publikováno v:
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners ISBN: 9783030165499
ALK and ROS1 positive NSCLC make up a small subset, around 5–7% of NSCLC overall. However, there are several targeted treatment options available to treat this type of lung cancer, all of which are superior to traditional chemotherapy response rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b604a75032453a06477fe7ede572351
https://doi.org/10.1007/978-3-030-16550-5_4
https://doi.org/10.1007/978-3-030-16550-5_4
Autor:
Marianne Davies, Beth Eaby-Sandy
This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about th
Publikováno v:
Journal of the Advanced Practitioner in Oncology. 9
Chemotherapy, and now targeted therapies and immunotherapies, are widely used for the management of patients with all stages of lung cancer. Some challenges present when patients are receiving concomitant hemodialysis for various comorbid conditions.